Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. (CGEM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cgem · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Cullinan Therapeutics, Inc. (CGEM) measures how much investors pay for each dollar of the company's trailing earnings. CGEM's current PE ratio of N/A is calculated by dividing its stock price of $13.22 by its TTM earnings per share of -$3.73.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2018 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Medical - Pharmaceuticals · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cullinan Therapeutics, Inc.You CGEM | $813M | N/A | — | -$3.73 |
 ADC Therapeutics S.A. ADCT | $119M | N/A | — | -$1.12 |
 Bicycle Therapeutics plc BCYC | $285M | N/A | — | -$3.16 |
 CeriBell, Inc. CBLL | $695M | N/A | — | -$1.46 |
 Enhabit, Inc. EHAB | $707M | N/A | — | -$0.09 |
 Standard BioTools Inc. LAB | $322M | N/A | — | -$0.20 |
 Neumora Therapeutics, Inc. Common Stock NMRA | $299M | N/A | — | -$1.45 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-3.72 | — | |
2024-12-31 FY2024 | — | $-3.11 | — | |
2023-12-31 FY2023 | — | $-3.69 | — | |
2022-12-31 FY2022 | 4.28x | $2.46 | — | |
2021-12-31 FY2021 | — | $-1.48 | — | |
2020-12-31 FY2020 | — | $-1.19 | — | |
2019-12-31 FY2019 | — | $-19.70 | — | |
2018-12-31 FY2018 | — | $-17.74 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cullinan Therapeutics, Inc. (CGEM) measures how much investors pay for each dollar of the company's trailing earnings. CGEM's current PE ratio of N/A is calculated by dividing its stock price of $13.22 by its TTM earnings per share of -$3.73.
Frequently asked questions
CGEM pe ratio · 6 questionsCGEM's current PE ratio is N/A as of 2026-06-08, based on a stock price of $13.22 and TTM EPS of -$3.73. Data sourced from Financial Modeling Prep via CGEM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cullinan Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08